Related Experiment Video

Updated: Oct 3, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

374

Considerations for the Primary Care Provider Caring for Patients with Juvenile Idiopathic Arthritis Receiving

Carolyn Zic

    Pediatric Annals
    |February 14, 2022
    PubMed

    Insights

    Juvenile idiopathic arthritis (JIA) is a common childhood autoimmune disease. Biologic therapies have improved JIA treatment outcomes, making understanding these medications crucial for primary care providers.

    Area of Science:

    • Pediatric Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Juvenile idiopathic arthritis (JIA) is the most frequent rheumatologic condition in children.
    • JIA is a chronic, autoimmune, incurable disease impacting over 1 in 1,000 children.
    • Biologic therapies, developed in the late 1990s, have significantly enhanced JIA patient prognoses.

    Purpose of the Study:

    • To inform primary care providers about biologic therapies for JIA.
    • To outline the side effects associated with JIA biologic medications.
    • To guide primary care providers in supporting pediatric patients undergoing biologic therapy.

    Main Methods:

    • Literature review on JIA and biologic therapies.
    • Analysis of treatment outcomes and side effect profiles.
    • Development of recommendations for primary care management.

    Main Results:

    • Biologic therapies have led to improved disease control and remission in JIA patients.
    • Understanding of medication mechanisms and potential adverse events is essential.
    • Primary care providers play a vital role in patient monitoring and support.

    Conclusions:

    • Primary care providers need foundational knowledge of JIA biologic treatments.
    • Effective management requires awareness of side effects and supportive care strategies.
    • Enhanced primary care involvement can optimize outcomes for children with JIA.

    More Related Videos

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    1.2K
    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    428

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
    249
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    282
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    220
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    232
    Therapeutic Drug Monitoring: Affecting Factors01:29

    Therapeutic Drug Monitoring: Affecting Factors

    Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
    8
    Drug Dosage Regimen: Overview01:15

    Drug Dosage Regimen: Overview

    A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
    Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
    3.9K